KDM1A and medulloblastoma: These include combination therapy with PI3K pathway inhibitors (BKM-120) and histone deacetylase inhibitors (LBH-589) for MYC-driven group 3 medulloblastoma, targeting LSD1 in MB with GFI1/GFI1B over-activation, CDK inhibitors, and cell cycle checkpoint inhibitors [37–39].